MedTrace Logo

Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma

NCT07036874 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2025-06-29

No results posted yet for this study

Summary

This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study. The study follow-up duration will be five years. The primary outcome is the composite of incident high-risk varices, hepatic decompensation and liver-related mortality. The participants will undergo transient elastography at baseline and then half-yearly post-HCC curative treatment; and oesophagogastroduodenoscopy (OGD) at baseline and then at year 1, 3 and 5 post-HCC curative treatment. Clinical assessments and laboratory tests will also be done at baseline and every 6 months until year 5 to identify any clinical events.

Conditions

  • HCC - Hepatocellular Carcinoma
  • Cirrhosis

Interventions

DIAGNOSTIC_TEST

transient elastography and oesophagogastroduodenoscopy

Liver and spleen stiffness will be measured by transient elastography. Varices will be identified by oesophagogastroduodenoscopy.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Jimmy CT Lai, MB ChB · Chinese University of Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-04
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07036874 on ClinicalTrials.gov